Zanarini Mary C, Frankenburg Frances R
Laboratory for the Study of Adult Development, McLean Hospital, Belmont, MA 02478, USA.
Am J Psychiatry. 2003 Jan;160(1):167-9. doi: 10.1176/appi.ajp.160.1.167.
The purpose of this study was to compare the efficacy of ethyl-eicosapentaenoic acid (E-EPA) and placebo in the treatment of female subjects with borderline personality disorder.
The authors conducted an 8-week, placebo-controlled, double-blind study of E-EPA in 30 female subjects meeting Revised Diagnostic Interview for Borderlines and DSM-IV criteria for borderline personality disorder.
Twenty subjects were randomly assigned to 1 g of E-EPA; 10 subjects were given placebo. Ninety percent of those in both groups completed all 8 weeks of the trial. Analyses that used random-effects regression modeling and controlled for baseline severity showed E-EPA to be superior to placebo in diminishing aggression as well as the severity of depressive symptoms.
The results of this study suggest that E-EPA may be a safe and effective form of monotherapy for women with moderately severe borderline personality disorder.
本研究旨在比较二十碳五烯酸乙酯（E-EPA）与安慰剂治疗边缘型人格障碍女性受试者的疗效。
作者对30名符合《边缘型人格障碍修订诊断访谈》及《精神疾病诊断与统计手册》第四版（DSM-IV）边缘型人格障碍标准的女性受试者进行了一项为期8周的E-EPA安慰剂对照双盲研究。
20名受试者被随机分配至服用1克E-EPA组；10名受试者服用安慰剂。两组中90%的受试者完成了全部8周的试验。采用随机效应回归模型并对基线严重程度进行控制的分析表明，E-EPA在减轻攻击性以及抑郁症状严重程度方面优于安慰剂。
本研究结果表明，E-EPA可能是治疗中度严重边缘型人格障碍女性的一种安全有效的单一疗法。
Zotero 插件